Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: Neurobiological background

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Brambilla, Francesca ^a   Amianto, Federico ^b   Dalle Grave, Riccardo ^c   Fassino, Secondo ^b  

^a SAN PAOLO HOSPITAL   (Italy)

^b University Department of Psychiatry   (Italy)

^c Department of Eating Disorders ^*  (Italy)

Author keywords

Anorexia nervosa; Biology; Bulimia nervosa; Pharmacotherapy; Psychotherapy

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN; OLANZAPINE; PAROXETINE; SEROTONIN TRANSPORTER; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ANOREXIA; ANOREXIA NERVOSA; ARTICLE; BINGE EATING DISORDER; BIOCHEMISTRY; BULIMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DISSOCIATION CONSTANT; DOPAMINE RELEASE; DRUG EFFICACY; EATING DISORDER; FEEDING BEHAVIOR; FEMALE; HUMAN; INDIVIDUAL PSYCHOLOGY BRIEF PSYCHOTHERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM BINDING CAPACITY; MENTAL DISEASE; MENTAL PATIENT; NEUROBIOLOGY; NORADRENALIN RELEASE; NORMAL VALUE; OUTPATIENT; PLASMA; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT; ANALYSIS OF VARIANCE; BLOOD; BULIMIA NERVOSA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; METABOLISM; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BULIMIA NERVOSA; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; PAROXETINE; PSYCHOTHERAPY, BRIEF; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT FAILURE;

EID: 84924148382     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0376-7     Document Type: Article

References (38)

1. NICE: Eating Disorders-Core Interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. In: NICE Clinical Guideline No. 9, National Institute for Clinical Excellence/Gaskell and the British Psychological Society, London/London; 2011.
2. Wilson TJ, Fairburn GC: Treatment for Eating Disorder. In A Guide to Treatments that Work. Edited by Nathan PE, Gorman JM. New York: Oxford University Press; 2007.
3. Fairburn CG, Cooper Z, O'Connor ME, Bohn K, Hawker DM, Wales JA, Palmer RL: Transdiagnostic Cognitive-Behavioral Therapy for patients with Eating Disorders: a two-site trial with 60-week follow-up. Am J Psychiatr 2009, 166(3):311-319.
4. Safer DL, Robinson AH, Jo B: Outcome from a randomized controlled trial of group therapy for Binge Eating disorder: comparing Dialectical Behavior Therapy adapted for Binge Eating to an Active Comparison group therapy. Behav Ther 2010, 41:106-120.
5. Aigner M, Treasure J, Kaye W, Kasper S, WFSBP Task Force On Eating Disorders: World Federation Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders. World J Biol Psychiatr 2011, 12:400-443.
6. Kaye WH, Frank GK, McConaha C: Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacol 1999, 21:503-506.
7. Frank GK, Bailer UF, Henry SE, Drevets V, Meltzer CC, Price JC, Mathis CA Wagner A, Hoge J, Ziolko S, Barbarich-Marsteller N, Weissfeld L, Kaye WH: Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11-CL] raclopride. Biol Psychiatr 2005, 58:908-912.
8. Wagner A, Aizenstein H, Mazurkewicz L, Fudge J, Frank GK, Putnam K, Bailer UF, Fischer L, Kaye WH: Altered insula response to taste stimuli in individuals recovered from restricting-type Anorexia Nervosa. Neuropsychopharmacol 2008, 33:513-523.
9. Kaye WH, Ebert MH, Raleigh M, Lake R: Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatr 1984, 41:350-355.
10. Kaye WH, Gwirtsman HE, George DT, Ebert H: 5HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatr 1988, 23:102-105.
11. Kaye WH, Gwirtsman HE, George DT, Ebert H: Altered serotonin activity in anorexia nervosa after long-term weight recovery. Arch Gen Psychiatr 1991, 48:556-562.
12. Kaye WH, Frank GK, Meltzer CC, Price JC, McKonaha CW, Crossan PJ, Klump KL, Rhodes L: Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatr 2001, 158:1152-1155.
13. Kaye WH, Barbarich NC, Putnam K, Gendall KA, Fernstrom J, Fernstrom M, McConaha CV, Kishore A: Anxiolitic effects of acute tryptophan depletion in anorexia nervosa. Int J Eat Dis 2003, 33:257-267.
14. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D: Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 2001, 26:393-409.
15. Bailer UF, Price JC, Meltzer CC, Mathis C, Frank GK, Wissfeld L, McConaha CW, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye WH: Altered 5-HT2a receptor binding after recovery from bulimia-type anorexia nervosa: relationship to harm avoidance and drive for thinness. Neuropsychopharmacol 2004, 29:1143-1155.
16. Bailer UF, Bloss C, Frank G, Meltzer C, Mathis CA, Geyer MA, Wagner A, Becker CR, Schork NJ, Kaye WH: 5-HT1A receptor binding is increased after recoveryfrom bulimia nervosa compared to control women and is associated with behavioural inhibition in both groups. Int J Eat Dis 2011, 44:477-487.
17. Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA, Wagner A, Barbarich-Marsteller NC, Bloss CS, Putman K, Schork NJ, Gamst A, Kaye WH: Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psychiatr Res 2013, 211:160-168.
18. Fairburn CG, Harrison PJ: Eating Disorders. Lancet 2003, 361:407-416.
19. Dalle Grave R: A multiple-step cognitive behaviour therapy for eating disorders. Eat Dis Rev 2005, 13:372-382.
20. Marazziti D: Pertugi G, Delitto J, Lenzi A, Maremmani I, Placidi GF, Cassano GB: High-affinity 3H-imiparmine binding sites: a possible state-dependent marker for major depression. Psychiatr Res 1988, 23:229-237.
21. Sternberg DE, Heninger GR, Roth RH: Plasma homovanillic acid as an index of brain dopamine metabolism: Enhancement with debrisoquin. Life Sci 1983, 32:2447-2452.
22. Glazer WM, Charney DS, Heninger GR: Noradrenergic function in schizophrenia. Arch Gen Psychiatr 1987, 44:898-904.
23. Rausch J, Johnson ME, Li J, Hutcheson J, Carr BM, Corley KM, Gowan AB, Smith J: Serotonin transporter kinetics correlated between human platelets and brain synaptosomes. Psychopharmacol 2005, 180:391.398.
24. Fassino S, Amianto F, Ferrero A: Brief Adlerian psychodynamic psychotherapy: theoretical Issues and process indicators. Panminerva Med 2008, 50:165-175.
25. Gerhardt GA, Drebing CJ, Freedman R: Simultaneous determination of free homovanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG) and vanyllilmandelic acid (VMA) in human plasma by HPLC coupled with dual electrode coulorimetric electrochemical detection. Anal Chem 1986, 58:2879-2883.
26. Monteleone P, Brambilla F, Bortolotti F, LaRocca A, Maj M: Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. Brit J Psychiatr 1998, 172:418-442.
27. Favaro A, Caregaro L, Burina AB, Santonastaso P: Tryptophan levels, excessive exercise, and nutritional status in anorexia nervosa. Psychosom Med 2000, 65:535-538.
28. Bruce KR, Steiger H, NG Ying Kin NMK, Israel M: Reduced platelet [3H]paroxetine binding in anorexia nervosa: relationship to eating symptoms and personality pathology. Psychiatr Res 2006, 142:225-232.
29. Eckman A, Sundblad-Elverfors C, Landeén M, Eriksson T, Eriksson E: Low density and high affinity of platelet [3H]paroxetine-binding in women with bulimia nervosa. Psychiatr Res 2006, 142:219-233.
30. Halmi KA, Dekirmeniijian H, Davis JM, Casper R, Goldberg S: Catecholamine metabolism in anorexia nervosa. Arch Gen Psychiatr 1978, 35:458-460.
31. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD: Symptom severity and neurotransmitter studies in bulimia. Psychopharmacol 1988, 96:124-129.
32. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D: Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinol 2001, 26:393-409.
33. Castro Formieles J, Deaulofeu R, Baeza I, Casulà V, Saura B, Labaro L, Puig J, Toro J, Bernardo M: Psychopathological and nutritional correlates of plasma homovanillic acid in adolescent with anorexia nervosa. J Psychiatr Res 2008, 42:213-220.
34. Kaye W: Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008, 94:121-135.
35. Vandereiken W, Pierlot R: Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1982, 66:445-450.
36. Vandereiken W: Neuroleptics in the short-term treatment of anorexia nervosa. A double- blind placebo-controlled study with sulpiride. Brit J Psychiatr 1984, 144:288-292.
37. Cassano GB, Miniati M, Pini S, Rotondo A, Banti S, Borri C, Camilleri V. Mauri M: Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J S Six Eat Dis 2003, 33:172-177.
38. Mondraty N, Birmingham CL, Touiz S, Sundakov V, Chapman L, Beaumont P: Randomized controlled trial of olanzapine in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol 2005, 13:72-75.